Geron’s the Biotech of the Day

Geron’s the Biotech of the Day
Geron saw its shares rise $1.72, or 25%, to $8.68 after the company said it has received a patent that could be used in stem-cell research. The process would be used, if it’s ever needed, to provide an additional level of safety for cell therapies made from human embryonic stem cells, the company said.


Leave a Reply

Your email address will not be published. Required fields are marked *

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Subscribe!